AQSTAquestive Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Aquestive Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AQSTEsta | $605M#7 | — | — | 13.6x#9 | -22.6%#12 | -89.8%#15 | -159.5%#10 | — | — | — | -6.2%#9 | — |
| ZVRA | $692M#1 | 12.5x#4 | 3.2x#9 | 6.5x#6 | 350.9%#3 | 178.9%#3 | -59.1%#7 | 38.2%#1 | — | — | 61.3%#4 | — |
| NGNE | $672M#2 | — | 3.1x#8 | — | -100.0%#15 | -20.2%#12 | — | -41.6%#10 | — | — | — | — |
| IRWD | $672M#3 | 5.1x#2 | — | 2.3x#4 | -15.7%#11 | 2629.5%#1 | 33.3%#2 | — | 42.6%#1 | — | 217.6%#2 | — |
| VSTM | $665M#4 | — | 13.3x#10 | 21.5x#10 | 209.1%#5 | -60.3%#14 | -550.3%#11 | -419.1%#12 | — | — | -25.3%#11 | — |
| PHAT | $659M#5 | — | — | 3.8x#5 | 216.9%#4 | 33.8%#9 | -91.4%#8 | — | — | 4#1 | -28.9%#12 | — |
| ALT | $628M#6 | — | 1.3x#3 | 15324.2x#13 | 105.0%#7 | 7.3%#10 | -230461.0%#14 | -18.6%#8 | -21.1%#4 | — | -10.0%#10 | — |
| FBIOP | — | 6.7x#3 | — | — | 9.7%#9 | 76.2%#5 | -111.0%#9 | 22.5%#3 | — | — | 110.5%#3 | — |
| CRMD | $604M#8 | 3.6x#1 | 1.3x#2 | 1.9x#2 | 617.0%#2 | 1009.4%#2 | 48.2%#1 | 35.4%#2 | — | — | -38.7%#13 | — |
| STTK | $599M#9 | — | 2.8x#7 | 599.2x#12 | -82.5%#14 | 35.3%#7 | -5150.8%#13 | -23.1%#9 | — | — | 233.5%#1 | — |
| CTMX | $588M#10 | — | 1.9x#5 | 7.7x#8 | -44.8%#13 | -154.5%#16 | -29.3%#5 | -5.7%#5 | -7.8%#3 | — | 35.7%#6 | — |
| ANNX | — | — | — | — | — | -49.6%#13 | — | -111.1%#11 | — | — | 58.1%#5 | — |
| ARVN | $541M#11 | 31.8x#6 | 1.0x#1 | 2.1x#3 | -0.3%#10 | 59.3%#6 | -45.1%#6 | -14.4%#7 | -25.3%#5 | — | — | — |
| ASMB | $531M#12 | 21.0x#5 | 1.7x#4 | 7.3x#7 | 153.5%#6 | 84.8%#4 | -16.8%#4 | -2.0%#4 | -4.4%#2 | — | 22.9%#7 | — |
| OVID | $529M#13 | — | 2.5x#6 | 73.0x#11 | 1181.3%#1 | 34.1%#8 | -585.2%#12 | -8.3%#6 | — | — | — | — |
| EOLS | $522M#14 | — | — | 1.8x#1 | 11.6%#8 | -2.4%#11 | -11.0%#3 | — | -40.5%#6 | 4#1 | 19.3%#8 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice